drugset / Trial / NCT00409383
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (LDH).
Timeline
- Start
- 2006-11
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |
| Subject | oblimersen sodium | Antisense oligonucleotide | 7 mg/kg | Intravenous |
| Subject | oblimersen sodium | Antisense oligonucleotide | 900 mg | Intravenous |